Next Issue
Volume 18, April
Previous Issue
Volume 17, September
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
2.6
Journals
Current Oncology
Volume 18
Issue 1
share announcement
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..

Curr. Oncol., Volume 18, Issue 1 (February 2011) – 15 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Section
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
3329 KiB  
Case Report
Acute Liver Failure Because of Chronic Lymphocytic Leukemia: Case Report and Review of the Literature
by Khashayar Esfahani, P. Gold, S. Wakil, R.P. Michel and S. Solymoss
Curr. Oncol. 2011, 18(1), 39-42; https://doi.org/10.3747/co.v18i1.756 - 01 Feb 2011
Cited by 11 | Viewed by 548
Abstract
Infiltration of the liver by hematologic malignancies is an uncommon cause of liver failure. B-Cell chronic lymphocytic leukemia (CLL) is a usually indolent disease that may infiltrate the liver, but based on a review of the literature, has never been reported [...] Read more.
Infiltration of the liver by hematologic malignancies is an uncommon cause of liver failure. B-Cell chronic lymphocytic leukemia (CLL) is a usually indolent disease that may infiltrate the liver, but based on a review of the literature, has never been reported to induce acute liver failure. Here, we describe the case of a 78-year-old woman with acute liver failure secondary to infiltration with CLL being unresponsive to chemotherapy and causing death. This case is notable because of its atypical presentation and ultimate poor prognosis. Full article
554 KiB  
Meeting Report
The Terry Fox Research Institute’s Ontario Dialogue: How Will Personalized Medicine Change Health Care?
by Kelly Curwin, C.J. Paige and S. Sutcliffe
Curr. Oncol. 2011, 18(1), 33-38; https://doi.org/10.3747/co.v18i1.834 - 01 Feb 2011
Cited by 1 | Viewed by 459
Abstract
This is the final instalment in a series of three articles by the Terry Fox Research Institute about its pan-Canadian dialogue series, Cancer: Let’s Get Personal, a public research and outreach project undertaken in 2010. The dialogues served to launch a national and [...] Read more.
This is the final instalment in a series of three articles by the Terry Fox Research Institute about its pan-Canadian dialogue series, Cancer: Let’s Get Personal, a public research and outreach project undertaken in 2010. The dialogues served to launch a national and continuing conversation on personalized medicine with the medical and scientific communities and the public, including cancer survivors, patients, and caregivers. Participants at the Ontario dialogue, held in Toronto, October 18, 2010, discussed the challenges that Canadians and the health care system face as they move forward on a pathway created by advanced science and technology that will phenomenally transform cancer care and treatment. The one-size-fits-all approach to treating cancer patients is being rapidly eclipsed by an approach that treats patients and their tumours as individually as possible. As a result, a paradigm shift is occurring both in the laboratory and in the clinic, creating new approaches to conducting research and delivering treatment and care that place each and every patient—and tumour—at the centre of treatment. New approaches and practices in health care are necessary to ensure successful uptake and implementation of these advances for the benefit of all Canadians. Participating partners and supporters of the Ontario dialogue were the Ontario Institute for Cancer Research and the University Health Network. Full article
524 KiB  
Article
Characterization of Published Errors in High-Impact Oncology Journals
by A. Molckovsky, M.M. Vickers and Patricia Tang
Curr. Oncol. 2011, 18(1), 26-32; https://doi.org/10.3747/co.v18i1.707 - 01 Feb 2011
Cited by 18 | Viewed by 712
Abstract
Purpose: To assess the frequency and propagation rate of published errors in the oncology literature and to determine possible contributing factors. Methods: We reviewed 10 major oncology journals to determine variability in the online presentation of errata. Canadian oncologists were surveyed regarding characteristics [...] Read more.
Purpose: To assess the frequency and propagation rate of published errors in the oncology literature and to determine possible contributing factors. Methods: We reviewed 10 major oncology journals to determine variability in the online presentation of errata. Canadian oncologists were surveyed regarding characteristics that may influence error propagation. Errors published during 2004–2007 in the Journal of Clinical Oncology (JCO) and the Journal of the National Cancer Institute (JNCI) were classified as trivial or serious (that is, whether change in outcome was involved). The frequency of citation and error propagation was determined for serious errors. Results: Of the 10 journals reviewed, 9 present links from the original article to the erratum; in 4 of those 9 journals, at least 1 link was missing. Survey results indicate that 33% of oncologists do not read errata, and 45% have read only the abstract when referencing an article. Although 59% of oncologists have noticed errors in cancer publications, only 13% reported the error. Together, jco and jnci published 190 errata, for an error rate of 4% ± 1% (standard deviation) annually; 26 of 190 errors were serious (14%). The median time from publication of the article to the corresponding erratum was 3.5 months for trivial errors as compared with 8.3 months for serious errors (p = 0.03). Error propagation in citations before and after publication of the erratum was 15% and 2% respectively (p < 0.01). Conclusions: Error rates in high-impact oncology journals average 4%, which is likely an underestimate, because errors noticed by readers are not consistently reported. Propagation of serious errors decreases, but still continues, after publication of errata. Full article
415 KiB  
Article
Oxaliplatin: A Review in the Era of Molecularly Targeted Therapy
by Thierry Alcindor and N. Beauger
Curr. Oncol. 2011, 18(1), 18-25; https://doi.org/10.3747/co.v18i1.708 - 01 Feb 2011
Cited by 296 | Viewed by 3838
Abstract
Objective: To review preclinical and clinical data for oxaliplatin in the current context of molecularly targeted therapy. Methods of Study Selection: We searched the PubMed and PubChem databases by combining the search terms “oxaliplatin” or “platinum” or both, with “clinical trials,” “pharmacokinetics,” and [...] Read more.
Objective: To review preclinical and clinical data for oxaliplatin in the current context of molecularly targeted therapy. Methods of Study Selection: We searched the PubMed and PubChem databases by combining the search terms “oxaliplatin” or “platinum” or both, with “clinical trials,” “pharmacokinetics,” and “pharmacodynamics”. Data Extraction and Synthesis: Oxaliplatin has a complicated pharmacokinetic profile, with activity against digestive cancers in particular. It has several mechanisms of action, but cancer cells can develop resistance. Real or potential synergism has been observed when oxaliplatin is combined with other cytotoxic agents or molecularly targeted agents. Peripheral neuropathy is a prominent toxic effect. Conclusions: Oxaliplatin lends itself to further clinical research in combination with molecularly targeted therapy. Full article
284 KiB  
Article
Weekly Paclitaxel in Ovarian Cancer—The Latest Success Story
by A. Jain, B. Dubashi, K. S. Reddy and P. Jain
Curr. Oncol. 2011, 18(1), 16-17; https://doi.org/10.3747/co.v18i1.680 - 01 Feb 2011
Cited by 12 | Viewed by 901
Abstract
Taxane and platinum combination chemotherapy forms the cornerstone for the management of epithelial ovarian cancer. [...] Full article
320 KiB  
Article
Evidence-Based Medicine: An Analysis of Prophylactic Bilateral Oophorectomy at Time of Hysterectomy for Benign Conditionsa
by Christine A. Larson
Curr. Oncol. 2011, 18(1), 13-15; https://doi.org/10.3747/co.v18i1.744 - 01 Feb 2011
Cited by 4 | Viewed by 650
Abstract
Sackett et al. defined evidence-based medicine as “the conscientious, explicit and judicious use of current best evidence in making decisions about the care of individual patients.” [...] Full article
288 KiB  
Article
Publishing in the Age of the Digital Doctor
by Richard I. Levin
Curr. Oncol. 2011, 18(1), 11-12; https://doi.org/10.3747/co.v18i1.796 - 01 Feb 2011
Viewed by 613
Abstract
We are living in the middle of a revolution. By the end of this Century of Biology, the fields of medicine and communications will seem utterly unfamiliar to us and would probably seem surreal to our forebears. [...] Full article
308 KiB  
Article
Knowledge Translation to Improve Cancer Control in Canada: A New Standing Series in Current Oncology
by Eva Grunfeld
Curr. Oncol. 2011, 18(1), 9-10; https://doi.org/10.3747/co.v18i1.825 - 01 Feb 2011
Cited by 2 | Viewed by 349
Abstract
With this editorial, Current Oncology is introducing a new standing series on knowledge translation to improve cancer control in Canada. [...] Full article
261 KiB  
Editorial
E-Manuscript Article Summaries
by Current Oncology Editorial Office
Curr. Oncol. 2011, 18(1), 6-8; https://doi.org/10.3747/co.v18i6.1000 - 01 Feb 2011
Viewed by 326
Abstract
The application of immunotherapeutic principles to the treatment and prevention of breast cancer has been ongoing for decades[...]. Full article
273 KiB  
Editorial
Breaking New Ground in a New Year
by Current Oncology Editorial Office
Curr. Oncol. 2011, 18(1), 5; https://doi.org/10.3747/co.v18i1.861 - 01 Feb 2011
Viewed by 315
Abstract
As 2011 begins, Current Oncology is pleased to announce a new initiative dubbed our “Cancer Knowledge Network.” [...] Full article
419 KiB  
Article
First- and Second-Line Therapy for Metastatic Urothelial Carcinoma of the Bladder
by F. A. Yafi, S. North and Wassim Kassouf
Curr. Oncol. 2011, 18(1), 695; https://doi.org/10.3747/co.v18i1.695 - 01 Feb 2011
Cited by 57 | Viewed by 837
Abstract
Urothelial cancer of the bladder is the 4th most common malignancy in American men and the 9th most common in women. Although it is a chemosensitive disease, advanced bladder cancer seems to have reached a plateau with regard to median survival of patients. [...] Read more.
Urothelial cancer of the bladder is the 4th most common malignancy in American men and the 9th most common in women. Although it is a chemosensitive disease, advanced bladder cancer seems to have reached a plateau with regard to median survival of patients. Standard first-line therapy remains gemcitabine plus cisplatin (GC) or methotrexate, vinblastine, doxorubicin, and cisplatin (MAVC). In patients deemed unfit to receive cisplatin, gemcitabine plus carboplatin or gemcitabine plus paclitaxel can be considered. To date, no standard therapy has been established for patients who recur or are refractory to first-line therapy. Second-line vinflunine, by way of superiority over best supportive care, has shown promise in a phase III trial. Cisplatin-based therapy (MAVC or GC) can also be offered to patients previously treated with cisplatin, especially if they responded previously and are considered platinum-sensitive. Novel targeted therapies are sorely needed to further improve the delivery and efficacy of chemotherapy. Full article
401 KiB  
Article
A Comparative Analysis of Monthly Out-of-Pocket Costs for Patients with Breast Cancer as Compared with Other Common Cancers in Ontario, Canada
by Christopher J. Longo and B. G. Bereza
Curr. Oncol. 2011, 18(1), 681; https://doi.org/10.3747/co.v18i1.681 - 01 Feb 2011
Cited by 46 | Viewed by 991
Abstract
Background: Monthly out-of-pocket costs (OOPC) for Ontario patients with cancer have previously been reported, but little detail has been provided on differences based on tumour type. Methods: A questionnaire administered in cancer clinics in the province of Ontario, with a mix [...] Read more.
Background: Monthly out-of-pocket costs (OOPC) for Ontario patients with cancer have previously been reported, but little detail has been provided on differences based on tumour type. Methods: A questionnaire administered in cancer clinics in the province of Ontario, with a mix of urban and rural patients, was analyzed using descriptive statistics and a regression analysis of cross-sectional data. The dependent variable was OOPC (Canadian dollars), analyzed separately for total OOPC (excluding imputed travel costs), and for each of the individual cost categories. Results: Compared with colorectal, lung, and prostate cancer patients combined, breast cancer patients had statistically significantly higher total OOPC ($393 vs. $149, p = 0.02), device costs ($142 vs. $12, p = 0.018), and family care costs ($38 vs. $3, p = 0.01). By contrast, they trended toward lower costs for travel ($225 vs. $426, p = 0.055) and had lower costs for parking ($32 vs. $53, p = 0.0198). Compared with non-breast cancer patients, patients with breast cancer reported a greater perceived financial burden (31% vs. 17% p = 0.0133). Interpretation: These findings highlight that financial burden for cancer patients can vary by tumour type, and that patients with breast cancer may require a different mix of supportive services than do patients with other common tumour types. Supportive care programs related to financial burden should consider the likelihood and nature of financial burden when counselling breast cancer patients. Full article
353 KiB  
Article
The Use and Effectiveness of Temozolomide in Children with Central Nervous System Tumours: A Survey from the Canadian Paediatric Brain Tumour Consortium
by Ute Bartels, S. Baruchel, A. S. Carret, B. Crooks, J. Hukin, D. Johnston, M. Silva, D. Strother, B. Wilson, S. Zelcer, D. Eisenstat, L. Sung and E. Bouffet
Curr. Oncol. 2011, 18(1), 675; https://doi.org/10.3747/co.v18i1.675 - 01 Feb 2011
Cited by 10 | Viewed by 588
Abstract
Objective: To describe the use of temozolomide (TMZ) in Canadian children treated for brain tumours and to evaluate survival and predictors of survival for children treated with this agent. Methods: A survey was conducted within the Canadian Paediatric Brain Tumour Consortium [...] Read more.
Objective: To describe the use of temozolomide (TMZ) in Canadian children treated for brain tumours and to evaluate survival and predictors of survival for children treated with this agent. Methods: A survey was conducted within the Canadian Paediatric Brain Tumour Consortium (CPBTC), a group of tertiary care centres in pediatric neurooncology (n = 16) in Canada that are involved in the treatment of children with central nervous system tumours. Results: In 10 of the 16 participating pediatric oncology centres of the CPBTC, 137 children with brain tumours were treated with TMZ between January 2000 and March 2006. Although 33% of the children were enrolled into a clinical trial, 67% were treated outside open studies. Most patients (72%) received TMZ treatment on recurrence of their brain tumour (first or subsequent). The most commonly administered regimen was single-agent TMZ 150–200 mg/ m2 administered on 5 consecutive days every 28 days. The median duration of TMZ treatment was 141 days (range: 4–1102 days). Response data were provided for 127 of the 137 patients, of whom 6 showed a complete response. Sixteen patients experienced a minor or partial response, 53 had stable disease, and 52 had progressive disease. Of 32 patients alive at last follow-up, 19 had a diagnosis of low-grade glioma. Full article
1217 KiB  
Article
Lymphangitic Metastasis of Recurrent Renal Cell Carcinoma to the Contralateral Lung Causing Lymphangitic Carcinomatosis and Respiratory Symptoms
by Jonathan B. Wallach, T. McGarry and J. Torres
Curr. Oncol. 2011, 18(1), 647; https://doi.org/10.3747/co.v18i1.647 - 01 Feb 2011
Cited by 12 | Viewed by 602
Abstract
Renal cell carcinoma comprises 80–85% of kidney malignancies. For early presentations, nephrectomy provides a high cure rate, but patients usually present at advanced stages, leading to poor outcomes. Even for patients without metastatic spread who undergo nephrectomy, metastatic recurrence is frequent. We report [...] Read more.
Renal cell carcinoma comprises 80–85% of kidney malignancies. For early presentations, nephrectomy provides a high cure rate, but patients usually present at advanced stages, leading to poor outcomes. Even for patients without metastatic spread who undergo nephrectomy, metastatic recurrence is frequent. We report the case of a patient who underwent nephrectomy for stage III renal cell carcinoma and who presented 20 months later with respiratory symptoms consistent with pneumonia, influenza, or (less likely) congestive heart failure or a cardiac event. Persistent right pleural effusion on serial chest radiographs despite treatment prompted computed tomography evaluation, which revealed lymphangitic carcinomatosis, a very rare form of renal cell carcinoma metastasis to the lung. This preliminary finding was confirmed by right middle lobe tissue biopsy through bronchoscopy and cytopathology examination. Full article
412 KiB  
Article
Immune Therapy for Breast Cancer in 2010—Hype or Hope?
by A. Florescu, E. Amir, N. Bouganim and Mark Clemons
Curr. Oncol. 2011, 18(1), 623; https://doi.org/10.3747/co.v18i1.623 - 01 Feb 2011
Cited by 27 | Viewed by 694
Abstract
The identification of numerous breast cancer antigens has generated increasing enthusiasm for the application of immune-based therapies in breast malignancies. Although the use of monoclonal antibodies has revolutionized the “targeted therapy” of breast cancer, and the immunomodulatory effects of bisphosphonates continue to be [...] Read more.
The identification of numerous breast cancer antigens has generated increasing enthusiasm for the application of immune-based therapies in breast malignancies. Although the use of monoclonal antibodies has revolutionized the “targeted therapy” of breast cancer, and the immunomodulatory effects of bisphosphonates continue to be evaluated, few studies to date have demonstrated widespread utility for other forms of immunotherapy. The present review assesses modern research and explores whether the hopes for immunotherapy can overcome the hype. Full article
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-15
Previous Issue
Next Issue
Back to TopTop